Hyperinsulinism in tyrosinaemia type I

被引:39
|
作者
Baumann, U
Preece, MA
Green, A
Kelly, DA
McKiernan, PJ
机构
[1] Birmingham Childrens Hosp, Liver Unit, Birmingham, W Midlands, England
[2] Birmingham Childrens Hosp, Dept Clin Chem, Birmingham, W Midlands, England
关键词
D O I
10.1007/s10545-005-5517-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tyrosinaemia type I (TT I) (McKusick 276700) is a heterogeneous disorder with a broad spectrum of clinical phenotypes. Although histological abnormalities of the pancreas are well recognized, there are only incidental reports of pancreatic dysfunction manifested as insulin-dependent diabetes mellitus. We report three subjects with TT I and acute liver dysfunction who had hyperinsulinism in early infancy. Hypoglycaemia persisted despite dietary treatment and one patient had inadequate lipolysis at the time of hypoglycaemia. All three patients were successfully treated with diazoxide (10 mg/kg per day) and chlorthiazide (35 mg/kg per day) and treatment was gradually withdrawn after 9, 13 and 34 months, respectively. The mechanism of pancreatic dysfunction in TT I is unknown but may be related to the toxic metabolites that accumulate in this condition. We conclude that hyperinsulinism is not a rare complication in TT I. In patients with persistent hypoglycaemia, C-peptide should always be measured. Treatment with diazoxide and chlorthiazide is highly effective, appears to be safe, and does not need to be continued lifelong.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 50 条
  • [1] Screening for tyrosinaemia type I
    Hutchesson, ACJ
    Hall, SK
    Preece, MA
    Green, A
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1996, 74 (03): : F191 - F194
  • [2] Mutation screening for tyrosinaemia type I
    Heath, SK
    Gray, RGF
    McKiernan, P
    Au, KM
    Walker, E
    Green, A
    JOURNAL OF INHERITED METABOLIC DISEASE, 2002, 25 (06) : 523 - 524
  • [3] Fumarylacetoacetase mutations in tyrosinaemia type I
    Rootwelt, H
    Hoie, K
    Berger, R
    Kvittingen, EA
    HUMAN MUTATION, 1996, 7 (03) : 239 - 243
  • [4] Liver transplantation in tyrosinaemia type I
    Baumann, U
    Rodeck, B
    MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (10) : 1102 - 1106
  • [5] Mutation screening for tyrosinaemia type I
    Heath, SK
    Gray, G
    Harper, A
    McKiernan, PJ
    Preece, M
    Green, A
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 206 - 206
  • [6] FANCONI SYNDROME SECONDARY TO TYROSINAEMIA TYPE I
    Rufach, A.
    Vique, C.
    Del Toro, M.
    Vazquez, A.
    Vilalta, R.
    Madrid, A.
    Lara, E.
    Nieto, J.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1854 - 1855
  • [7] Tyrosinaemia Type I. A New Theraphy
    E Raimann
    A Valiente
    M Jímenez
    L Muñoz
    G Durán
    V Cornejo
    Pediatric Research, 1998, 44 (5) : 815 - 815
  • [8] Abnormal glutathione conjugation in patients with tyrosinaemia type I
    Mulders, TMT
    Bergman, DJW
    PollThe, BT
    Smit, GPA
    Breimer, DD
    Mulder, GJ
    Duran, M
    Smeitink, JAM
    JOURNAL OF INHERITED METABOLIC DISEASE, 1997, 20 (04) : 473 - 485
  • [9] NTBC as palliative treatment in chronic tyrosinaemia type I
    Ros, J
    Vilaseca, MA
    Lambruschini, N
    Mas, A
    Lindstedt, S
    Holme, E
    JOURNAL OF INHERITED METABOLIC DISEASE, 1999, 22 (05) : 665 - A666
  • [10] Alterations of hepatic peroxisomes in tyrosinaemia type I: Return to fetal type?
    Kerckaert, I
    de Koning, TJ
    Poll-The, BT
    Roels, F
    JOURNAL OF INHERITED METABOLIC DISEASE, 1998, 21 (03) : 186 - 190